Dr. Lyttle has served as Chairman of the Radius Scientific Advisory Board since June 2012. He previously served as President and CEO of Radius from September 2004 to December 2011 and interim Chief Scientific Officer from December 2011 to June 2012. Dr. Lyttle served as Executive Chairman of Karos Pharmaceuticals from July 2010 to November 2013. Previously, he was Vice President of Discovery for Women’s Health and Bone as well as Head of the Women’s Health Research Institute at Wyeth. At Wyeth, he directed drug discovery in women’s health for several areas including menopause, contraception, reproductive disorders, osteoarthritis, osteoporosis, and urinary incontinence. Under his leadership, Wyeth advanced 17 new product candidates into preclinical and clinical development, including the SERM, bazedoxifene; Tanaproget, a novel non-steroidal contraceptive; and DVS-233 for vasomotor symptoms associated with menopause. Prior to joining Wyeth, Dr. Lyttle was Research Professor of Obstetrics, Gynecology, and Pharmacology at the University of Pennsylvania. He received a PhD in Biochemistry from Queen’s University, Kingston, Ontario, followed by postdoctoral research at the Population Council at the Rockefeller University, and the University of Chicago.